Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: High rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Blood

Volumn 118, Issue 3, 2011, Pages 703-711

  Pagel, John M ^a,b   Kenoyer, Aimee L ^a   Bäck, Tom ^c   Hamlin, Donald K ^b   Wilbur, D Scott ^b   Fisher, Darrell R ^d   Park, Steven I ^a,b   Frayo, Shani ^a   Axtman, Amanda ^a   Orgun, Nural ^a   Orozco, Johnnie ^a,b   Shenoi, Jaideep ^a,b   Lin, Yukang ^a   Gopal, Ajay K ^a,b   Green, Damian J ^a,b   Appelbaum, Frederick R ^a,b   Press, Oliver W ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; BISMUTH 213; CD45 ANTIGEN; RADIOISOTOPE; STREPTAVIDIN; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; SURVIVAL TIME; TUMOR XENOGRAFT;

EID: 79960684246     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347039     Document Type: Article

References (48)

1. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549-556. (Pubitemid 37185088)
2. Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm. 2002;17(2):151-163. (Pubitemid 34507415)
3. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98(3):565-572.
4. Ringhoffer M, Blumstein N, Neumaier B, et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130(4):604-613. (Pubitemid 43899765)
5. Schwartz MA, Lovett DR, Redner A, et al. Doseescalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11(2):294-303. (Pubitemid 23046820)
6. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85(4):1122-1131.
7. Pagel JM, Appelbaum FR, Eary JF, et al. 131Ianti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184-2191. (Pubitemid 43289405)
8. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100(4):1233-1239. (Pubitemid 34864277)
9. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94(4):1237-1247.
10. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009;114(27):5444-5453.
11. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24(5):823-834. (Pubitemid 46671186)
12. Pagel J, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101(6):2340-2348. (Pubitemid 36302079)
13. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood. 2008;111(4):2261-2268. (Pubitemid 351451433)
14. Pagel JM, Matthews DC, Kenoyer A, et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res. 2009;69(1):185-192.
15. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res. 2006;66(7):3884-3892.
16. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl 1):199S-204S.
17. Park SI, Shenoi J, Pagel JM, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116(20):4231-4239.
18. Wilbur DS, Park SI, Chyan MK, et al. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. Bioconjug Chem. 2010;21(7):1225-1238.
19. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97(4):1802-1807. (Pubitemid 30118523)
20. Hui TE, Fisher DR, Kuhn JA, et al. A mouse model for calculating cross-organ beta doses from yttrium-90- labeled immunoconjugates. Cancer. 1994;73(3 suppl):951-957. (Pubitemid 24046655)
21. Back T, Jacobsson L. The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles. J Nucl Med. 2010;51(10):1616- 1623.
22. Jaggi JS, Kappel BJ, McDevitt MR, et al. Efforts to control the errant products of a targeted in vivo generator. Cancer Res. 2005;65(11):4888-4895. (Pubitemid 40740828)
23. Fisher DR, Badger CC, Brietz H, et al. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antibody Immunoconj Radiopharm. 1991;4:655.
24. Ballangrud AM, Yang WH, Charlton DE, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled antiprostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61(5):2008-2014.
25. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259-1266.
26. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-2463. (Pubitemid 34525730)
27. Jurcic JG, Scheinberg DA. Radionuclides as conditioning before stem cell transplantation. Curr Opin Hematol. 1999;6(6):371-376. (Pubitemid 29503143)
28. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713. (Pubitemid 34507123)
29. Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy. 2008;10(1):13-20.
30. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32(5):601-614. (Pubitemid 41214204)
31. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004;48(4):289-296.
32. Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: providing a further rationale for clinical investigation. J Nucl Med. 2006;47(8):1238-1240. (Pubitemid 47544873)
33. Waldmann T. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. Leuk Lymphoma. 2003;44(suppl 3):S107-S113. (Pubitemid 38196070)
34. Song EY, Qu CF, Rizvi SM, et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther. 2008;7(1):76-80. (Pubitemid 351590456)
35. Humm JL, Chin LM, Macklis RM. F(ab′)2 fragments versus intact antibody: an isodose comparison [comment]. J Nucl Med. 1990;31(6):1045-1047. (Pubitemid 20186250)
36. Supiot S, Faivre-Chauvet A, Couturier O, et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer. 2002;94(4 suppl):1202-1209. (Pubitemid 34150879)
37. Behr TM, Behe M, Stabin MG, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999;59(11):2635-2643. (Pubitemid 29269111)
38. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100(1):208-216. (Pubitemid 35177449)
39. Friesen C, Glatting G, Koop B, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res. 2007;67(5):1950-1958. (Pubitemid 46424211)
40. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294(5546):1537-1540. (Pubitemid 33063927)
41. Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem. 2006;17(6):1551-1560. (Pubitemid 44851502)
42. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451-4459. (Pubitemid 40834252)
43. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45(1):129-137. (Pubitemid 47611619)
44. Dahle J, Borrebaek J, Jonasdottir TJ, et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood. 2007;110(6):2049-2056. (Pubitemid 47443922)
45. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys. 2006;64(5):1503-1512.
46. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alphaparticle-emitting actinium daughters. J Am Soc Nephrol. 2005;16(9):2677-2689.
47. Back T, Haraldsson B, Hultborn R, et al. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab′)2: a long-term study of renal function in nude mice. Cancer Biother Radiopharm. 2009;24(6):649-658.
48. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100(4):1891-1895. (Pubitemid 36254544)